Developer docs
API playgroundTry for free, no card

Search company profiles

MVM Life Science Partners

Full company profile

uuid0000d98

Namestring
MVM Life Science Partners
Legal namestring
MVM Partners LLP
Websiteurl
mvm.com
Company typeenum
Private
Founded yearint
1997
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, life sciences investment, growth equity capital, medical technology investment, venture capital
Industry1 code
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Healthcare Private Equity
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Private Equity Fund Management
TypeLicensing Royalties
Description

MVM generates returns through equity investments in healthcare companies, partnering with management teams to build world-class companies and achieve successful exits through acquisitions and IPOs. The firm has completed 42 exits since founding in 1997.

mvm.com
2Portfolio Company Returns
TypeTransaction Fee
Description

Investment returns realized through exits - recent notable exits include Nalu Medical (acquired by Boston Scientific for ~$533M in 2025), Optinose (acquired by Paratek), and other strategic acquisitions.

mvm.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Fund Management
ModelOtherBilling cadenceMulti-year contract
Notes

Private equity fund management with typical investment range of $20-100 million per portfolio company over the holding period. Larger investments possible for unique financing opportunities.

mvm.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MVM Partners LLP provides growth-stage equity capital and strategic partnership to healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. The firm partners with management teams to bring innovative products to market, drive growth, execute strategic acquisitions, and establish new standards of care, sourcing return from capital appreciation and exits (acquisitions and IPOs) across its concentrated portfolio.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 42 successful exits since founding in 1997
+4 more records
Product overview1 text field

MVM Partners is a life science private equity firm that provides equity investment and strategic support to high-growth healthcare businesses. The firm invests across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. Rather than offering a unified software product, MVM operates as a financial investment partnership that deploys capital in the $20-100 million range per portfolio company, working closely with management teams to accelerate growth and scale innovative healthcare companies. The firm's portfolio includes companies such as GT Medical Technologies (GammaTile radiation therapy for brain tumors), Neurent Medical (NEUROMARK System for chronic rhinitis), ProVerum (ProVee System for BPH), Avanzanite (rare disease pharmaceutical distribution), and various other medical device and healthcare technology companies.

Product and service1 record
1MVM Private Equity Investment Services
CategoryHealthcare Private Equity Investment
Description

Equity capital and strategic partnership for healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. Targeted at management teams of growth-stage healthcare businesses with differentiated technology addressing significant unmet needs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1EQT Life Sciences
TypeDirect peer
Description

EQT Life Sciences (formerly LSP) is a healthcare-focused growth equity firm based in the Netherlands, investing across medical devices, pharma, and diagnostics across Europe and the US — directly comparable to MVM in stage focus, check size, and European-US footprint.

TypeDirect peer
Description

Paris-based Sofinnova is one of Europe's largest healthcare-only venture capital firms with €4B+ AUM, investing across medtech, biotech, and digital health from early to late stage — a near-direct peer that has co-invested alongside MVM in Neurent Medical.

TypeDirect peer
Description

Dutch healthcare-focused PE/VC firm investing in medtech, therapeutics, and digital health across Europe and the US — directly comparable to MVM in sector focus and stage, and a recurring co-investor (ProVerum, GT Medical).

TypeDirect peer
Description

Forbion is a leading European healthcare-dedicated VC firm with multi-billion AUM, investing across pharma, medtech, and digital health from seed to late-stage — directly comparable to MVM in sector mandate and transatlantic coverage.

TypeDirect peer
Description

OrbiMed is one of the world's largest healthcare-dedicated investment firms with $17B+ AUM across venture, growth, and public strategies — a direct sector peer that co-invested with MVM in ProVerum's Series B.

TypeDirect peer
Description

Abingworth is a UK-headquartered healthcare-only investment firm with global reach, investing across all stages of therapeutics, medtech, and digital health — comparable to MVM in sector specialization, geography, and stage range.

TypeDirect peer
Description

Ampersand is a Boston-based healthcare and life sciences-focused PE firm investing in pharma services, medical devices, and specialty healthcare — directly comparable to MVM in sector focus and check size.

TypeDirect peer
Description

Atlas Venture is a Boston/Cambridge-based early-stage venture firm focused on biotech and healthcare — comparable to MVM in healthcare-only mandate, though biased toward earlier stages.

TypeBroad incumbent
Description

Novo Holdings manages the Novo Nordisk Foundation's investment portfolio with substantial healthcare/biotech allocations globally — a broader incumbent that competes for similar deals but with a much larger capital base and broader sector mandate.

TypeBroad incumbent
Description

Bain Capital Life Sciences is a dedicated healthcare investment platform within Bain Capital, deploying large growth and buyout capital across therapeutics, medtech, and healthcare services — a broader incumbent competing for the same healthcare innovation deals as MVM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment89 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MVM Life Science Partners

Healthcare Private Equitymvm.com

MVM Life Science Partners firmographics

Firmographics
Name
MVM Life Science Partners
Legal name
MVM Partners LLP
Website
https://mvm.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

MVM Life Science Partners industry classification

Industry
Product category
Healthcare Private Equity
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms

Keywords

  • Healthcare private equity
  • Life sciences investment
  • Growth equity capital
  • Medical technology investment
  • Venture capital

Where MVM Life Science Partners is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

MVM Life Science Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Private Equity Fund Management: MVM generates returns through equity investments in healthcare companies, partnering with management teams to build world-class companies and achieve successful exits through acquisitions and IPOs. The firm has completed 42 exits since founding in 1997.
  2. Portfolio Company Returns: Investment returns realized through exits - recent notable exits include Nalu Medical (acquired by Boston Scientific for ~$533M in 2025), Optinose (acquired by Paratek), and other strategic acquisitions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFund Management

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

MVM Life Science Partners product offering

Product offering

Core offering

MVM Partners LLP provides growth-stage equity capital and strategic partnership to healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. The firm partners with management teams to bring innovative products to market, drive growth, execute strategic acquisitions, and establish new standards of care, sourcing return from capital appreciation and exits (acquisitions and IPOs) across its concentrated portfolio.

Product overview

MVM Partners is a life science private equity firm that provides equity investment and strategic support to high-growth healthcare businesses. The firm invests across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. Rather than offering a unified software product, MVM operates as a financial investment partnership that deploys capital in the $20-100 million range per portfolio company, working closely with management teams to accelerate growth and scale innovative healthcare companies. The firm's portfolio includes companies such as GT Medical Technologies (GammaTile radiation therapy for brain tumors), Neurent Medical (NEUROMARK System for chronic rhinitis), ProVerum (ProVee System for BPH), Avanzanite (rare disease pharmaceutical distribution), and various other medical device and healthcare technology companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • MVM Private Equity Investment Services Equity capital and strategic partnership for healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. Targeted at management teams of growth-stage healthcare businesses with differentiated technology addressing significant unmet needs.

Quantifiable outcome

  • 42 successful exits since founding in 1997
  • +4 more outcomes

Companies that use MVM Life Science Partners

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles1 record

MVM Life Science Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MVM Life Science Partners partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

MVM Life Science Partners competitors and assessment

Company assessment

Direct peers

  • EQT Life Sciences: EQT Life Sciences (formerly LSP) is a healthcare-focused growth equity firm based in the Netherlands, investing across medical devices, pharma, and diagnostics across Europe and the US — directly comparable to MVM in stage focus, check size, and European-US footprint.
  • Sofinnova Partners: Paris-based Sofinnova is one of Europe's largest healthcare-only venture capital firms with €4B+ AUM, investing across medtech, biotech, and digital health from early to late stage — a near-direct peer that has co-invested alongside MVM in Neurent Medical.
  • Gilde Healthcare Partners: Dutch healthcare-focused PE/VC firm investing in medtech, therapeutics, and digital health across Europe and the US — directly comparable to MVM in sector focus and stage, and a recurring co-investor (ProVerum, GT Medical).
  • Forbion: Forbion is a leading European healthcare-dedicated VC firm with multi-billion AUM, investing across pharma, medtech, and digital health from seed to late-stage — directly comparable to MVM in sector mandate and transatlantic coverage.
  • OrbiMed: OrbiMed is one of the world's largest healthcare-dedicated investment firms with $17B+ AUM across venture, growth, and public strategies — a direct sector peer that co-invested with MVM in ProVerum's Series B.
  • Abingworth: Abingworth is a UK-headquartered healthcare-only investment firm with global reach, investing across all stages of therapeutics, medtech, and digital health — comparable to MVM in sector specialization, geography, and stage range.
  • Ampersand Capital Partners: Ampersand is a Boston-based healthcare and life sciences-focused PE firm investing in pharma services, medical devices, and specialty healthcare — directly comparable to MVM in sector focus and check size.
  • Atlas Venture: Atlas Venture is a Boston/Cambridge-based early-stage venture firm focused on biotech and healthcare — comparable to MVM in healthcare-only mandate, though biased toward earlier stages.

Broad incumbents

  • Novo Holdings (Novo Ventures): Novo Holdings manages the Novo Nordisk Foundation's investment portfolio with substantial healthcare/biotech allocations globally — a broader incumbent that competes for similar deals but with a much larger capital base and broader sector mandate.
  • Bain Capital Life Sciences: Bain Capital Life Sciences is a dedicated healthcare investment platform within Bain Capital, deploying large growth and buyout capital across therapeutics, medtech, and healthcare services — a broader incumbent competing for the same healthcare innovation deals as MVM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MVM Life Science Partners social profiles

Digital presence

MVM Life Science Partners compliance and trust

Trust signal

Compliance1 record

MVM Life Science Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MVM Life Science Partners leadership team

Management profile

Number of profiles

Profiles20 records

MVM Life Science Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MVM Life Science Partners M&A and investment

M&A and investment

M&A

Investments89 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MVM Life Science Partners

What does MVM Life Science Partners do?

MVM Partners LLP provides growth-stage equity capital and strategic partnership to healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. The firm partners with management teams to bring innovative products to market, drive growth, execute strategic acquisitions, and establish new standards of care, sourcing return from capital appreciation and exits (acquisitions and IPOs) across its concentrated portfolio.

Is MVM Life Science Partners a public or private company?

MVM Life Science Partners is a private company. It is classified as management employee owned and is currently operating.

When was MVM Life Science Partners founded?

MVM Life Science Partners was founded in 1997. It employs 11 to 50 people.

Where is MVM Life Science Partners based?

MVM Life Science Partners is headquartered in Boston, United States, in the North America region.

How does MVM Life Science Partners make money?

Two revenue lines are on record. Private Equity Fund Management is the primary driver. The others are portfolio Company Returns.

Who are MVM Life Science Partners's main competitors?

Direct peers on record are EQT Life Sciences, Sofinnova Partners, Gilde Healthcare Partners, Forbion, OrbiMed, Abingworth, Ampersand Capital Partners and Atlas Venture. Broad incumbents are Novo Holdings (Novo Ventures) and Bain Capital Life Sciences.

Does MVM Life Science Partners have an API?

No public API is recorded for MVM Life Science Partners.

What industry is MVM Life Science Partners in?

MVM Life Science Partners's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 523940 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Irish TimesBrian Shields: ‘I spent years watching patients struggle with conditions that had poor or no solutions’Brian Shields, founder and CEO of Neurent Medical, founded the Galway-based medical device company in 2014 after identifying an unmet need in rhinitis treatment while participating in a BioInnovate fellowship at University of Galway. The company has developed Neuromark, a single-use device for ENT specialists providing non-surgical symptom relief, and has grown to treat approximately 20,000 patients while securing over 60 patents. Neurent has raised €150 million across three funding rounds from investors including Fountain Healthcare Partners, EQT Lifesciences, and MVM Partners, with the most recent Series C raise of €62 million led by US firm MVM Partners.Mpo-magGT Medical Tech Pockets $100M in Oversubscribed Series EGT Medical Technologies closed an oversubscribed $100 million Series E financing led by Viking Global Investors. The funds will support commercial and operational initiatives after ROADS trial data showed a 93% reduction in tumor reoccurrence and 41% in death at 12 months. Proceeds will also expand the BRIDGES trial for glioblastomas.FinSMEsGT Medical Technologies Raises $100M in Series E FundingGT Medical Technologies raised $100M in Series E funding led by Viking Global Investors. The company will use the funds to accelerate commercial and operational initiatives and support its BRIDGES RCT in glioblastoma patients. The company develops GammaTile, a bioresorbable radioactive tile for immediate targeted radiation.Medical Device NetworkNeurent secures $74m to expand NEUROMARK commercial activitiesNeurent Medical has closed an oversubscribed Series C financing round, raising €62.5m ($74m) to expand commercial activities for its NEUROMARK system targeting chronic rhinitis, generate additional clinical evidence, and further develop its product pipeline. MVM Partners led the financing with participation from Sofinnova Partners, alongside continued support from Atlantic Bridge, EQT Life Sciences, Enterprise Ireland, and Fountain Healthcare Partners. The company, headquartered in Galway, Ireland with operations in Braintree, Massachusetts, also added MVM partner Kyle Dempsey and Sofinnova partner Cedric Moreau to its board of directors.BioSpaceAvanzanite Bioscience Secures €32M Series A Investment from MVM PartnersAvanzanite Bioscience B.V., a Dutch specialty pharmaceutical company focused on rare diseases, has secured a €32 million Series A growth investment from MVM Partners, a leading global life-science private equity firm, marking MVM's first institutional investment in the company. The funding will be used to scale Avanzanite's pan-European infrastructure across all 32 European markets, accelerate rare disease product launches, and support new strategic alliances and asset acquisitions. Avanzanite reported strong momentum with Q3 2025 revenue tripling year-on-year and growing over 20% quarter-on-quarter, having formed three strategic alliances and launched three rare disease medicines since its founding in 2022.AvanzaniteAvanzanite Bioscience Secures €32M Series A Investment from MVM Partners – Avanzanite BioscienceAvanzanite Bioscience B.V., a Amsterdam-based commercial-stage specialty pharmaceutical company focused on rare diseases, announced a €32 million Series A growth investment from MVM Partners, making MVM its first institutional investor and joining its Board of Directors. The funding will scale Avanzanite's pan-European infrastructure across 32 countries, propel current and future rare disease product launches, and enable new strategic alliances and asset acquisitions. Avanzanite reported Q3 2025 revenue tripling year-on-year with over 20% quarter-on-quarter growth, having entered three strategic alliances and launched three rare disease medicines across nephrology, ophthalmology and haematology in just three years.Silicon CanalsAmsterdam’s Avanzanite secures €32M Series AAmsterdam-based Avanzanite Bioscience BV, a company developing treatments for rare diseases, raised €32 million in a Series A funding round led by MVM Partners. The funds will support its expansion across Europe, new product launches, strategic partnerships, and asset acquisitions, with plans to establish a pan-European platform for orphan medicine commercialization.Business Wire BlogAvanzanite Bioscience Secures €32M Series A Investment from MVM PartnersAvanzanite Bioscience, a Dutch commercial-stage specialty pharmaceutical company focused on rare diseases, secured a €32 million Series A investment from MVM Partners, a global life-science private equity firm. The funding will accelerate pan-European expansion, enable strategic alliances and asset acquisitions, and support the company's goal of building more than ten rare disease alliances by 2032. Avanzanite reported record-breaking Q3 2025 performance with revenue tripling year-on-year and growing over 20% quarter-on-quarter.